Breast cancer with postoperative depressive symptoms Cancer
Conditions
Interventions
This randomized, double-blind, controlled trial enrolled 108 breast cancer patients who underwent modified radical mastectomy between July 2020 and March 2023. All patients were assessed with the Hami
Sponsors
The First Affiliated Hospital of University of South China
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. HAMD-17 score between 8 and 24 (mild to severe depressive symptoms) 2. Age range between 18 and 65 years 3. American Society of Anesthesiologists (ASA) physical status classification of I-II 4. Confirmed diagnosis of breast cancer and planned unilateral radical mastectomy for breast cancer
Exclusion criteria
Exclusion criteria: 1. HAMD-17 score of greater than 24 or less than 7 2. Other psychiatric disorders (e.g., schizophrenia and bipolar disorder) 3. History of psychiatric disorders prior to the study 4. Patients who have used psychotropic medications or have other serious systemic illnesses (including serious heart, kidney, or liver disease) 5. Contraindication or allergy to the use of esketamine 6. Planned surgery other than radical mastectomy alone (e.g., reconstruction)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale (HAMD-17) scores at baseline and 6 months postoperatively | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. HAMD-17 score changes at baseline (pre-surgery) and 6 months post-surgery 2. Patient demographic data (age, weight, height, pathology type)measured by review of patient medical records at the time of enrollment | — |
Countries
China
Contacts
Public ContactHaifan Xu
Outcome results
None listed